Biotechnology

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2023-01-03 14:10 2790

Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023

Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research SAN JOSE, Calif., Dec. 29, 2022 /PRNewswire/ -- Complete Genomics Inc(https://completegenomics.mgiamericas.com/), a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting...

2022-12-30 01:58 2955

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company d...

2022-12-29 23:25 3508

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

SUZHOU, China, Dec. 26, 2022 /PRNewswire/ -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs , and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), ann...

2022-12-26 23:01 3376

CJ CheilJedang, and Emmyon, Inc. sign a Licensing Agreement to commercialize a dietary supplement with natural extracts for use in significant improvement of skeletal muscle mass and function in humans.

SEOUL, South Korea and ROCHESTER, Minn., Dec. 26, 2022 /PRNewswire/ -- CJ Food and Nutrition Tech (CJ FNT), a newly formed business unit of CJ CheilJedang, a South Korea based global food and nutrition company, and Emmyon, Inc., a privately-held biotechnology start-up company based inRochester, MN...

2022-12-26 21:00 3901

Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- Nuevocor , a pre-clinical stage cardiac gene therapy company, announced today that it will be presenting at the Biotech Showcase during JPM week, taking place inSan Francisco, CA, USA from January 9 to 11, 2023. Nuevocor will als...

2022-12-21 22:00 3169

QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

SHANGHAI, Dec. 20, 2022 /PRNewswire/ --  QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineeredBiopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical D...

2022-12-21 10:30 4033

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...

2022-12-21 08:00 3352

PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

NANJING, China, Dec. 20, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by Simcere with Shanghai Institute ofMateria Medica (the "SIMM") and Wuhan Institute of Virology (the "WIV"), Chines...

2022-12-20 19:21 3031

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

SHANGHAI and MOSCOW, Dec. 20, 2022 /PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9M...

2022-12-20 17:00 3041

SeekIn Receives CE-IVD Mark Approval for PanCanSeek® Cancer Mutation Detection Kit

First-of-its-kind one-for-all cancer mutation detection test SHENZHEN, China, Dec. 19, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for PanCanSeek® Cancer Mutation Detection Kit...

2022-12-19 21:00 2204

TG ImmunoPharma (TGI) announces FDA clearance of IND application for TGI-2, a novel anti-PVRIG therapeutic antibody

HEFEI, China, Dec. 17, 2022 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (Hefei, China), an innovative biotech company dedicated to the discovery of novel immunotherapeutic drugs and a leader in NK cell research globally, today announced that the U.S. Food and Drug Administration (FDA) has cleared i...

2022-12-17 21:30 3168

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Depar...

2022-12-16 08:44 3055

BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

* A leader in creating jobs through the advancement of RNA-based therapeutics * A contributor to a high employment rate in Korea's healthcare industry BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South K...

2022-12-15 21:00 2170

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]  which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...

2022-12-14 21:52 2698

Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022

GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...

2022-12-14 01:40 2717

Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates

Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...

2022-12-13 18:00 2460

Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL

SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...

2022-12-13 17:39 2601

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...

2022-12-12 21:50 3015

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...

2022-12-12 21:00 2921
1 ... 121122123124125126127 ... 165